Holographic Mm-Wave Imaging in Patients Undergoing Radiation Therapy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03789773 |
Recruitment Status :
Recruiting
First Posted : December 31, 2018
Last Update Posted : May 3, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Unspecified Adult Solid Tumor | Device: Millimeter-Wave Holographic Imaging | Not Applicable |
PRIMARY OBJECTIVES:
I. To obtain patient images in a clinical setting and assess their quality.
SECONDARY OBJECTIVES:
I. To assess the registration agreement through a voxel-voxel distance-to-agreement metric.
OUTLINE:
Patients undergo holographic mm-wave imaging in radiotherapy treatment position after initial computed tomography (CT) simulation.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 10 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | Holographic Mm-wave Imaging in Radiation Oncology |
Actual Study Start Date : | December 14, 2018 |
Estimated Primary Completion Date : | December 14, 2020 |
Estimated Study Completion Date : | June 15, 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: Diagnostic (holographic mm-wave imaging)
Patients undergo holographic mm-wave imaging in radiotherapy treatment position after initial CT simulation.
|
Device: Millimeter-Wave Holographic Imaging
Undergo mm-wave holographic imaging
Other Name: Holographic Millimeter-wave Imaging; Holographic mm-Wave Imaging; MMW Holographic Imaging; Millimeter-wave Imaging; MMW Imaging; MMW |
- Qualitative assessment of holographic image quality [ Time Frame: Up to 1 year ]Qualitative assessment of image quality by study physicians according to the scoring of each image as: 1 = High Quality (A); 2= Acceptable Quality (B); 3 = Poor/Unacceptable Quality (C). Lower value (1) represents a better score than higher value (3). There are no subscales and or total scores. The quality scores of the images will be tabulated.
- Image registration agreement between mm-wave holographic images and a cone-beam computed tomography (CBCT)/optical surface image [ Time Frame: Up to 1 year ]The distribution of the percent of points in voxel-voxel analysis to agree to better than 2 mm will be tabulated

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Patients who are scheduled to receive either an optical or CBCT imaging scan as part of their treatment management.
- The study will be open to English and Spanish speaking participants.
Exclusion Criteria:
- Patients that are not scheduled for fluoroscopic or optical imaging as part of the normal course of radiotherapy.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03789773
United States, California | |
USC / Norris Comprehensive Cancer Center | Recruiting |
Los Angeles, California, United States, 90033 | |
Contact: Michael Reilly, PhD 708-951-1100 Michael.reilly@med.usc.edu | |
Principal Investigator: Michael Reilly, PhD |
Principal Investigator: | Michael Reilly | University of Southern California |
Responsible Party: | University of Southern California |
ClinicalTrials.gov Identifier: | NCT03789773 History of Changes |
Other Study ID Numbers: |
0S-18-6 NCI-2018-02994 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) 0S-18-6 ( Other Identifier: USC / Norris Comprehensive Cancer Center ) P30CA014089 ( U.S. NIH Grant/Contract ) |
First Posted: | December 31, 2018 Key Record Dates |
Last Update Posted: | May 3, 2019 |
Last Verified: | May 2019 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Device Product Not Approved or Cleared by U.S. FDA: | No |
Pediatric Postmarket Surveillance of a Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |